Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2967406 | 0.95 | HRH3 (0.60) | L3MBTL1L3MBTL3HRH3KCNH2L3MBTL4 | |
| SCHEMBL2966380 | 0.91 | HRH3 (0.65) | L3MBTL1L3MBTL3HRH3KCNH2 | |
| SCHEMBL29706010 | 0.88 | L3MBTL3 (0.58) | L3MBTL1L3MBTL3HRH3KCNH2L3MBTL4 | |
| SCHEMBL31262623 | 0.82 | L3MBTL1 (0.50) | L3MBTL1L3MBTL3HRH3KCNH2KDM4E | |
| SCHEMBL20788470 | 0.82 | ALDH1A1 (0.56) | L3MBTL1L3MBTL3HRH3KDM4EALDH1A1 | |
| SCHEMBL642288 | 0.82 | ALDH1A1 (0.55) | L3MBTL1L3MBTL3HRH3KCNH2KDM4E | |
| SCHEMBL1427022 | 0.82 | ALDH1A1 (0.57) | L3MBTL1L3MBTL3HRH3KDM4EALDH1A1 | |
| SCHEMBL24185702 | 0.81 | L3MBTL3 (0.63) | L3MBTL1L3MBTL3HRH3L3MBTL4SCN9A | |
| SCHEMBL2377708 | 0.81 | POLB (0.54) | L3MBTL1HRH3KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1872354 | 0.80 | ALDH1A1 (0.59) | L3MBTL1L3MBTL3HRH3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2023-11-23 | — | — | US | disclosed |
| WO-2022011337-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011338-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | ORIGENIS GMBH (DE) | 2022-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373985-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, MAPKAPK2, MAP3K20 | L3MBTL1 2031/4885L3MBTL3 2148/4885HRH3 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.